Siemens Healthineers AG banner

Siemens Healthineers AG
XMUN:SHL

Watchlist Manager
Siemens Healthineers AG Logo
Siemens Healthineers AG
XMUN:SHL
Watchlist
Price: 34.2 EUR
Market Cap: €38.3B

Wall St Price Targets

SHL Price Targets Summary
Siemens Healthineers AG

Wall Street analysts forecast SHL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SHL is 49.32 EUR with a low forecast of 37.52 EUR and a high forecast of 63.26 EUR.

Lowest Forecast
Price Target
37.52 EUR
10% Upside
Average Forecast
Price Target
49.32 EUR
44% Upside
Highest Forecast
Price Target
63.26 EUR
85% Upside
Siemens Healthineers AG Competitors:
Price Targets
NTGR
NETGEAR Inc
53% Upside
ZIP
Ziprecruiter Inc
2% Upside
9688
Zai Lab Ltd
50% Upside

Revenue
Forecast

6% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
6% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 9 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 5%.

Gross Profit
Forecast

6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 9 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 6%.

Operating Income
Forecast

5% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
5% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 9 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 3 years is 15%.

Pre-Tax Income
Forecast

5% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
5% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 15%.

Net Income
Forecast

6% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss
6% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Over the last 9 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 3 years is 16%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SHL's stock price target?
Price Target
49.32 EUR

According to Wall Street analysts, the average 1-year price target for SHL is 49.32 EUR with a low forecast of 37.52 EUR and a high forecast of 63.26 EUR.

What is the Revenue forecast for Siemens Healthineers AG?
Projected CAGR
5%

Over the last 9 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 5%.

What is the Gross Profit forecast for Siemens Healthineers AG?
Projected CAGR
6%

Over the last 9 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 6%.

What is the Operating Income forecast for Siemens Healthineers AG?
Projected CAGR
15%

Over the last 9 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 3 years is 15%.

What is the Pre-Tax Income forecast for Siemens Healthineers AG?
Projected CAGR
15%

Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 15%.

What is the Net Income forecast for Siemens Healthineers AG?
Projected CAGR
16%

Over the last 9 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 3 years is 16%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett